Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of ($1.21), $0.18 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.